A Study of Enzalutamide and LY3023414 in Men with Prostate Cancer
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.
Your participation could last up to 56 days or longer if you are tolerating the study drug and your study doctor thinks your condition is stable or improving.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Participant must have diagnosis of prostate cancer
Participant must have metastatic disease
Participant must have completed and failed prior abiraterone treatment
Participant must be surgically or medically castrated
Participant must be able to swallow the study drug (pills) whole
Participant must not have had prior treatment with chemotherapy or enzalutamide
Participant must not have known brain metastases or uncontrolled hypertension
Participant must not have insulin-dependent diabetes mellitus, however participants with type 2 diabetes mellitus may be eligible
Participant must not have an active, known fungal, bacterial, and/or known viral infection